FDA
Top dvm360 articles of 2023: #15
We have compiled a countdown of our top 15 articles in 2023, here is number 15
FDA issues Priority Zoonotic Animal Drug draft guidance
The federal agency is is accepting public comments until February 16, 2024.
FDA issues warnings of unapproved antimicrobial animal drugs
Nine manufacturers and distributors received warning letters with concerns about federal law violations
FDA renews conditional approval of medication for chemotherapy-induced diarrhea
Canalevia-CA1 is the first treatment for this indication to receive the agency's support at this level
FDA determines drug for lifespan extension in large dogs to have a Reasonable Expectation of Effectiveness
Celine Halioua, founder and CEO of Loyal, discussed the potential of LOY-001, a developmental therapy, with dvm360.
FDA extends comment period for draft guidance on certain antimicrobial drugs
Feedback for draft GFI #273 can be submitted until January 5, 2024.
Zoetis officially launches 2 FDA approved drugs in the US veterinary market
Librela and Apoquel Chewable were approved earlier this year and are now available on the market
FDA reveals reauthorization of Animal Drug User Fee programs
The programs will be administered by the FDA until 2028
FDA’s new 5-year plan for antimicrobial stewardship in animals is released
The agency’s Center for Veterinary Medicine has set forth its goals for the 2024 to 2028 fiscal years
FDA releases Animal and Veterinary Innovation Agenda
The agenda is a step toward the FDA modernizing its approach to evaluating and supporting creating innovative animal and veterinary products.